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We hypothesized that sepsis during hyperglycemia would activate left ventricular (LV) mitogen activated protein kinase (MAPK)
signaling mechanisms and modulate generation of endothelin-1 (ET-1) and nitric oxide (NO) that can contribute to the progression of LV
dysfunction. A single injection of streptozotocin (STZ, 60 mg/kg, via tail vein) was used to produce type 2 diabetes in male SD rats.
Polymicrobial sepsis and sham-sepsis were induced using single i.p. injection of cecal inoculum and sterile 5% dextrose water, respectively,
on the 13th and 27th day following STZ injection. Both 2-week (2-wk) and 4-wk diabetes groups were associated with hyperglycemia and
weight loss. LV end diastolic pressure (LVEDP) was significantly increased in 4-wk diabetes but not in 2-wk diabetes group. Plasma
concentration of tumor necrosis factor-alpha (TNF-a) was significantly increased in 4-wk diabetes + sepsis group as compared to sham, 2-wk
diabetes + sepsis and sepsis groups. Elevated plasma and LV ET-1 and NO byproducts (NOx) along with LV preproET-1 and inducible nitric
oxide synthase (iNOS) protein expression were observed in 4-wk but not in 2-wk diabetes group. Sepsis further elevated LV iNOS and
preproET-1 in 4-wk diabetes group. Up-regulated phosphorylation of LV p38-MAPK, extracellular signal-regulated kinase 1/2 (ERK1/2) and
heat shock protein-27 (Hsp27) was observed in 4-wk diabetes group. Sepsis caused a factorial increase in LV p38-MAPK and Hsp27
phosphorylation and iNOS up-regulation but not ERK1/2 following progression from 2-wk to 4-wk diabetes. The study provides evidence
that sepsis up-regulated LV iNOS, p38-MAPK phosphorylation and elevated LVEDP during 4-wk diabetes. We concluded that sepsis
contributes in the development of LVEDP dysfunction and alteration in signaling mechanisms depending upon the progression from 2-wk to
4-wk diabetes in the rat.
D 2004 Elsevier B.V. All rights reserved.Keywords: Diabetes; SIRS; Signaling; Endothelin-1; Nitric oxide synthase; Left ventricular end diastolic pressure
1. Introduction and characterized by elevated left ventricular end diastolicDiabetes is a complex and multifarious group of disor-
ders characterized by hyperglycemia that has reached epi-
demic proportions in the present century. Infection is a
leading cause of morbidity and mortality among the diabetic
population [1]. A higher frequency of occurrence of septic
shock following surgical procedures has been observed in
diabetic patients [2]. Infection inflicted by both gram-
positive and gram-negative bacteria initiates systemic in-
flammatory response syndrome (SIRS) leading to sepsis,
septic shock and end-organ failure [3]. Both diabetes and
polymicrobial sepsis are associated with myocardial injury0925-4439/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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formance and alterations in regional vascular perfusion [4–
7]. However, the influence of sepsis on diabetes-induced
altered myocardial function and underlying stress-induced
molecular signaling mechanisms has not been characterized
yet.
Mitogen activated protein kinases (MAPKs) are impli-
cated in the etiology of sepsis and diabetes [8,9]. MAPKs
are serine-threonine protein kinases involved in cell surviv-
al, proliferation and apoptosis [10]. Three MAPK subfami-
lies have been well characterized: extracellular signal
regulated kinase 1 and 2 (ERK1/2), c-jun N-terminal kinases
(JNK) and p38-MAPK [11]. ERK1/2 is involved in the
growth response of cell while p38-MAPK and JNK are
associated with cellular response to stress [11], inflamma-
tion [12] and vasoactive mediators such as endothelin-1
Table 1
Experimental design for induction of diabetes and sepsis in rats randomized
to the following groups
Group Number Treatments
of animals
1st day 13th day 27th day
Sham 6 Saline D5W D5W
Sepsis (24 h) 6 C.I. – –
D2 6 STZ – –
D4 6 STZ – –
D2 + sepsis 6 STZ C.I. –
D4 + sepsis 6 STZ – C.I.
C.I., cecal inoculum in sterile 5% dextrose water (D5W); D2, 2-wk dia-
betes group; D4, 4-wk diabetes group; D2 + sepsis, 2-wk diabetes + sepsis
group; D4+ sepsis, 4-wk diabetes + sepsis group, STZ, Streptozotocin (60
mg/kg, iv).
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ible nitric oxide synthase (iNOS) expression in serum-
deprived RAW 264.7 cells [14]. These observations suggest
that signaling mechanisms can regulate various vasoactive
molecules and vice versa. Although a differential regulation
of p38-MAPK and ERK1/2 depending upon the duration
and severity of diabetes has been demonstrated [15], the
effect of sepsis in the regulation of MAPK signaling
mechanism during diabetes is not known.
We have earlier demonstrated that diabetes during coro-
nary artery bypass grafting and chronic peritoneal sepsis
produced an imbalance in the myocardial and systemic ET-1
and nitric oxide (NO) profiles [6,16]. However, the precise
role of ET-1 following sepsis during diabetes is unclear.
Diabetes, both type 1 and type 2, is associated with
decreased NO bioavailability [17,18]. Conflicting reports
(i.e. increased, unchanged and decreased) exist regarding
the state of iNOS and endothelial NOS (eNOS) during
diabetes [19–21]. We have earlier reported that elevation
of ET-1 and NO mechanisms, either systemically or locally,
in the myocardium correlated well with the development of
myocardial dysfunction during sepsis [6] and make the heart
susceptible for a myocardial injury [22]. We anticipate that,
depending upon the duration of hyperglycemia, sepsis
would modulate systemic and myocardial ET-1 and NO
mechanisms, and ventricular function. Therefore, in the
present study we hypothesized that sepsis during hypergly-
cemia would activate LV MAPK signaling mechanisms and
modulate the generation of ET-1 and NO that can contribute
to the progression of myocardial dysfunction. To address
this hypothesis, we determined: (1) if induction of sepsis
depending upon the duration of hyperglycemia using a STZ-
induced type 2 rat model would modulate LV p38-MAPK
and ERK1/2 phosphorylation, and (2) if sepsis-induced
alterations in the systemic and local levels of ET-1 and
NO would correlate with LVEDP dysfunction during 2-
week (wk) and 4-wk diabetes.2. Materials and methods
Male Sprague–Dawley rats (Harlan, IN, USA) weighing
350–400 g were used in the study. The rats were acclima-
tized to the laboratory conditions for at least 7 days
following their arrival. All animal experiments were con-
ducted in compliance with humane animal care standards
outlined in the NIH Guide for the Care and Use of
Experimental Animals and were approved by the Institu-
tional Animal Care and Use Committee of North Dakota
State University.
2.1. Experimental protocol
All animals were age-matched at the onset of the study.
The rats were randomly divided into three groups: sham, 2-
wk and 4-wk diabetic rats (n = 12 for each group) (Table 1).2.1.1. Induction of diabetes
Diabetes was produced by a single tail vein injection of
streptozotocin (STZ; 60 mg/kg, i.v.). The induction of
diabetes was confirmed by blood glucose estimation (Gluc-
ometer EliteR, Bayer, IN) 24 h after STZ-injection. Diabetes
was confirmed if blood glucose >200 mg/dl, and monitored
at different time intervals throughout the study. The animals
were not given insulin supplementation.
2.1.2. Induction of sepsis
Sepsis was induced in the animals using cecal inoculum
(200 mg/kg, i.p.) as previously described [6]. Briefly, cecal
inoculum was prepared by mixing cecal contents (200 mg)
obtained from donor rats (euthanitized with pentobarbital;
100 mg/kg, i.p.) with 5 ml of 5% dextrose water to yield a
concentration of 40 mg/ml. The cecal inoculum was pre-
pared fresh each day and cecal material from one donor rat
was used within 2 h for three to five experimental animals.
The nondiabetic sham rats received an injection of 1 ml/kg
saline. The animals in each group were then further subdi-
vided into sham and sepsis groups. Two or four weeks post-
STZ administration, recordings of systemic hemodynamics,
heart rate (HR), systolic blood pressure (SBP), diastolic blood
pressure (DBP) and LV pressure were done. Arterial blood
was collected in plastic tubes containing EDTA (1 mg/ml)
and heparin (5 units/ml) to determine the plasma concentra-
tion of ET-1, NO by-products (NOx) and tumor necrosis
factor-a (TNF-a). The animals were euthanitized by pento-
barbital (100 mg/kg, iv) and LV tissue was harvested. The
concentration of ET-1, NOx and protein expression of iNOS,
eNOS, preproET-1, phosphorylated p38-MAPK (pp38-
MAPK), total p38-MAPK, total and phosphorylated ERK1/
2 and phosphorylated heat shock protein-27 (Hsp-27) were
determined in LV tissue obtained from each animal.3. Surgical protocol
Separate groups of animals (N = 6) were used for hemo-
dynamic study. On the day of experiment, the rats were
anesthetized with an intraperitoneal injection of pentobarbital
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then laid ventrally and through a cervical midline incision
right carotid artery was catheterized using a polyethylene
cannula (PE-50, internal diameter 0.58mm, external diameter
0.965 mm, Clay Adams Division, Becton Dickinson and Co.,
Parsippany, NJ). The catheter inserted in the right carotid
artery was further advanced to the left ventricle to obtain LV
pressure tracings. Once the presence of the cannula tip in the
left ventricle was confirmed (as evident by the waveform
tracing), the cannula was kept in position. Tail artery cannu-
lation was performed for arterial blood pressure recording.
Hemodynamic data were collected using transducers (TSD
104A) connected to LV cannula and tail artery cannula.
Transducers were connected to multichannel Biopac data
acquisition system attached to a computer. The data were
collected at a sampling rate of 1000 Hz and analyzed by
employing the software Acqknowledge. Prior to acquisition,
the transducers were calibrated at 0 and 200 mm Hg using a
standard mercury sphygmomanometer. The catheters were
tunneled subcutaneously and exited at the back of the neck of
the animals. The surgical wounds were sutured using sterile
non-absorbable silk sutures (Ethicon, Johnson & Johnson)
and animals were returned to individual cages. Mean arterial
pressure (MAP) was calculated as [MAP=(SBP + 2DBP)/3].
Rate of change of LV contraction ( + dP/dt) and relaxation
( dP/dt) were calculated as the first derivative of LV
pressure over time. Rate pressure product (RPP), an indicator
of myocardial oxygen demand, was calculated as a product of
SBP and HR.4. Biochemical estimations
4.1. Concentration of TNF-a in plasma
The plasma concentration of TNF-a was determined
using a rat TNF-a EIA kit (R&D systems, Minneapolis,
MN). The rat TNF-a assay has no cross-reactivity with the
other cytokines like Interleukin-1 (IL-1), IL-2 and IL-4.
4.2. Concentration of ET-1 in plasma and LV tissue
The concentration of ET-1 was determined in plasma and
LV tissue using a commercially available EIA kit (Assay
Designs Inc., Ann Arbor, MI). Briefly, the blood samples
were collected in plastic tubes containing EDTA (1 mg/ml)
before euthanasia. The samples were centrifuged at
3000 g (Centra-8R, IEC, MA) for 15 min at 4 jC and
plasma were separated. Plasma was then acidified adding an
equal volume of 20% acetic acid. The LV tissue samples
were weighed and homogenized using Polytron homoge-
nizer (Brinkman Instruments, Westbury, NY). The tissue
homogenate was centrifuged at 49000 g (Beckman Coul-
ter, Palo Alto, CA) for 15 min at 4 jC and the supernatant
was collected in plastic tubes. The smaller peptides were
extracted from plasma and supernatants using SEP-columns[6,23] and then assayed for ET-1 using an EIA kit from
Assay Designs. The ET-1 assay has < 0.1% cross-reactivity
with related peptides like bigET-1.
4.3. Concentration of NOx in plasma and LV tissue
The concentration of NO byproducts NOx (nitrate + ni-
trite) was determined in LV tissue and plasma as previously
described [6,23] using Griess reagent. The blood samples
immediately after collection were spun down at 5000 rpm for
10 min. The plasma was then decanted and stored at  20 jC
until the time of NOx determination. The LV tissue was
homogenized with cold phosphate buffered saline (PBS) on
ice that inhibited the activity of NOS ex vivo. The homog-
enate was spun down (3000 g, 5 min, Beckman) and the
supernatant was collected. The NOx concentration was then
determined in the supernatant using Greiss reaction method.
4.4. Immunoblot analysis
The LV tissue samples were homogenized in lysis buffer
and centrifuged. Following the technique of Pollock et al.
[24] the homogenized samples were electrophoresed on 10%
denaturing sodium dodecyl sulfate polyacrylamide gels. The
proteins were transferred electrophoretically to polyvinyli-
dene difluoride (PVDF) membrane (Gelman Sciences,
Pierce, Rockford, IL). Uniform loading was assessed by h-
actin protein expression. Nonspecific binding sites on the
membrane were blocked with 5% nonfat dry milk in Tris–
HCl containing 0.2% Tween-20 buffer (TBST) overnight at 4
jC. The membranes were then exposed to primary antibody
for 1 h at room temperature. After five washings in TBST the
membranes were incubated with the secondary antibody for 1
h at room temperature. Finally membranes were washed three
times with TBST. The specific proteins were detected by
enhanced chemiluminescence (ECL reagent, Amersham
Pharmacia Biotech). The blots were analyzed using Un-
Scan-It software to estimate the density of the blots in pixels.
4.5. Statistical analyses
All the data were expressed as meanF S.E. The hemo-
dynamic and biochemical data were analyzed using one-
way ANOVA using SPSS software. When a significant F
value was obtained, post hoc Students Newman Keul’s test
was performed for inter- and intra-group comparisons.
Statistical significance was realized at PV 0.05 to approve
the null hypothesis for individual parameters.5. Results
5.1. General characteristics of animals
Diabetes induction using STZ (at both 2 wk and 4 wk)
significantly increased blood glucose levels and reduced
Table 2
General characteristics of experimental animals
Group Body
weight (g)
Heart
weight (g)
Blood glucose
(mg/dl)
Sham 390.1F13.7 1.46F 0.07 121F16
Sepsis (24 h) 358.7F 8.4 1.45F 0.03 134F 17
D2 324.5F 15.7* 1.35F 0.06 426F 57*
D4 312.1F 9.2* 1.28F 0.06* 446F 42*
D2 + sepsis 323.4F 15.9* 1.30F 0.1 381F 77*,#
D4 + sepsis 308.3F 18.3*,# 1.23F 0.05*,# 513F 28*,#,a
D2, 2-wk diabetes group; D4, 4-wk diabetes group; D2 + sepsis, 2-wk
diabetes + sepsis group; D4 + sepsis, 4-wk diabetes + sepsis group. (N= 5 in
each group).
a PV 0.05 as compared to respective 2-wk diabetes group.
*PV 0.05 as compared to age-matched sham group.
# PV 0.05 as compared to age-matched sepsis group. Fig. 1. Effect of sepsis on the plasma concentration of TNF-a in sham and
diabetic (2-wk and 4-wk) rats (N= 6 in each group). Data are expressed as
meanF S.E. D2, 2-wk diabetes group; D4, 4-wk diabetes group;
D2 + sepsis, 2-wk diabetes + sepsis group; D4 + sepsis, 4-wk diabetes +
sepsis group. *PV 0.05 as compared to sham-treated group, #PV 0.05 as
compared to sepsis group, aPV 0.05 as compared to respective 2-wk group,
zPV 0.05 as compared to 4-wk diabetes group.
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sham and septic counterparts. Although the heart weights
were comparable in sham, sepsis and 2-wk diabetic rat
groups, the 4-wk diabetic and 4-wk diabetic + septic animals
had a significantly reduced heart weight as compared to the
sham group (Table 2). The mortality observed in the present
study during 2-wk and 4-wk diabetes was 20% and 26%,
respectively.
The septic animals uniformly displayed piloerection,
lethargy, periocular discharge, and diarrhea, and post-mor-
tem analysis revealed the presence of ascites and infarcts on
peritoneal organs. Induction of sepsis in diabetic rats pro-
duced profusely ulcerated peritoneal cavity that had an
extremely foul-smelling fluid with ascites.
5.2. Systemic hemodynamics
Sepsis significantly increased LVEDP at 24 h as com-
pared to sham. Although 2-wk diabetes did not alter LVEDP,
it was significantly elevated in 4-wk diabetes group as
compared to sham and 2-wk diabetes group. Sepsis increased
LVEDP in both 2-wk and 4-wk diabetes groups as compared
to sham. LVEDP in the 4-wk diabetes + sepsis group was
also significantly increased as compared to sepsis and 2-wkTable 3
Systemic hemodynamics of experimental animals
Group MAP
(mm Hg)
HR
(bpm)
LVEDP
(mm Hg)
Sham 130.3F 3.3 419F 5 4.4F 0.4
Sepsis (24 h) 115.3F 9.6 471F11* 7.4F 0.6*
D2 120.4F 6.4 326F 7* 5.2F 0.5
D4 117.4F 2.9 339F 10* 8.6F 0.7*,a
D2 + sepsis 121.2F 8.1 365F 18*,#,y 7.1F 0.8*,y
D4+ sepsis 116.3F 7.1 382F 19#,z 11.1F1.9*,#,a
MAP, mean arterial pressure; HR, heart rate; LVEDP, left ventricular end diastolic
2-wk diabetes + sepsis group; D4+ sepsis, 4-wk diabetes + sepsis group. (N= 5 i
a PV 0.05 as compared to respective 2-wk diabetes group.
*PV 0.05 as compared to age-matched sham group.
# PV 0.05 as compared to age-matched sepsis group.
y PV 0.05 as compared to 2-wk diabetes group.
z PV 0.05 as compared to 4-wk diabetes group.diabetes + sepsis groups. No differences in MAP were ob-
served in any of the groups studied. A significant increase in
HR in sepsis group was observed as compared to sham. Both
2-wk and 4-wk diabetes produced a significant decrease in
HR as compared to sham. Although sepsis in 2-wk and 4-wk
diabetic rats significantly increased HR as compared to
respective diabetes group, the values were still significantly
lower than in sham and sepsis groups. RPP was significantly
decreased in 2-wk and 4-wk diabetes groups as compared to
sham. Sepsis significantly decreased RPP in 2-wk and 4-wk
diabetic rats as compared to sepsis group. Although there
was no change in  dP/dt in any of the groups, + dP/dt was
significantly decreased in sepsis, 2-wk diabetes and 4-wk
diabetes + sepsis groups as compared to sham (Table 3).
5.3. Concentration of TNF-a in plasma
Sepsis produced a significant increase in plasma TNF-a
concentration as compared to sham. Sepsis in 4-wkRPP ( 1000)
(mm Hg. bpm)
+ dP/dt ( 1000)
(mm Hg/s)
 dP/dt ( 1000)
(mm Hg/s)
67.3F 3.7 14.0F 0.3 10.1F 0.3
67.8F 7.5 9.0F 1.4* 9.2F 2.0
47.9F 3.2* 9.9F 1.1* 7.2F 1.1
47.9F 2.7* 11.2F 0.7 6.6F 0.4
53.3F 5.7# 11.1F1.4 7.4F 0.9
50.6F 3.9*,# 9.0F 1.1* 7.5F 1.6
pressure; D2, 2-wk diabetes group; D4, 4-wk diabetes group; D2 + sepsis,
n each group).
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plasma TNF-a as compared to sham, respective 4-wk
diabetes and 2-wk diabetes + sepsis groups. Plasma TNF-
a concentration in 2-wk and 4-wk diabetes groups and 2-
wk diabetes + sepsis group were not different than sham
group (Fig. 1).
5.4. Concentration of ET-1 in plasma and LV tissue
The concentration of ET-1 in plasma and LV tissue was
not altered in sepsis and 2-wk diabetes groups as com-
pared to sham. Four-week diabetes group displayed a
significant elevation in plasma and LV ET-1 levels as
compared to sham. Sepsis significantly increased ET-1
concentration in plasma and LV tissue in both 2-wk andFig. 2. Effect of sepsis on (A) concentration of ET-1 in plasma (N= 6) (B
expression of preproET-1 (N = 3 in each group) in the left ventricular tissue o
expression depicts uniform loading in gel. Data are expressed as meanF S.E.
diabetes group; D4, 4-wk diabetes group; D2 + sepsis, 2-wk diabetes + sepsis
to sham-treated group, #PV 0.05 as compared to sepsis group, aPV 0.05 as
diabetes group.4-wk diabetes group as compared to sham and sepsis
groups (Fig. 2A and B).
5.5. Protein expression of LV preproET-1
To determine the effect of sepsis on LV ET-1 during dia-
betes, we determined the expression of ET-1 precursor, pre-
proET-1 in addition to ET-1 levels. A significant elevation in
LV preproET-1 protein expression was observed in 4-wk dia-
betes but not in 2-wk diabetes group as compared to sham and
2-wk diabetes groups. Induction of sepsis in 2-wk and 4-wk
diabetes group significantly increased LV preproET-1 ex-
pression as compared to sham. However, LV preproET-1 in 4-
wk diabetes + sepsis group was significantly higher as com-
pared to sepsis and 2 wk diabetes + sepsis groups (Fig. 2C).) concentration of ET-1 in left ventricular tissue (N= 6) (C) protein
btained from sham and diabetic (2-wk and 4-wk) rats. h-Actin protein
The blot is a representative of three independent experiments. D2, 2-wk
group; D4+ sepsis, 4-wk diabetes + sepsis group, *PV 0.05 as compared
compared to respective 2-wk group, yPV 0.05 as compared to 2-wk
Biophysica Acta 1690 (2004) 42–53 475.6. Concentration of NOx in plasma and LV tissue
A significant elevation in the concentration of NOx in
plasma but not in LV tissue was observed in sepsis group
as compared to sham. Two-week diabetes did not alter the
concentration of NOx in plasma and LV tissue as com-
pared to sham. However, 4-wk diabetes significantly
increased the concentration of NOx in plasma and LV
tissue as compared to sham and 2-wk diabetes group.
Sepsis in both 2-wk and 4-wk diabetes groups further
elevated plasma and LV NOx levels significantly as
compared to sham, sepsis and respective diabetes groups.
Also 4-wk diabetes + sepsis group significantly increased
both plasma and LV NOx levels as compared to 2-wk
diabetes + sepsis group (Fig. 3).
5.7. Protein expression of LV iNOS and eNOS
Sepsis significantly increased the protein expression of
iNOS (Fig. 4A) and decreased eNOS (Fig. 4B) in LV
A. Gupta et al. / Biochimica etFig. 3. Effect of sepsis on the concentration of NOx in plasma (A) and left
ventricular tissue (B) obtained from sham and diabetic (2-wk and 4-wk) rats
(N = 6 in each group). Data are expressed as meanF S.E. D2, 2-wk diabetes
group; D4, 4-wk diabetes group; D2 + sepsis, 2-wk diabetes + sepsis group;
D4 + sepsis, 4-wk diabetes + sepsis group. *PV 0.05 as compared to sham-
treated group, #PV 0.05 as compared to sepsis group, aPV 0.05 as compared
to respective 2-wk group, yPV 0.05 as compared to 2-wk diabetes group
and zPV 0.05 as compared to 4-wk diabetes group.tissue as compared to sham. Two-week diabetes group
did not exhibit any changes in LV iNOS and eNOS as
compared to sham. Four-week diabetes significantly in-
creased iNOS and decreased eNOS expression in LV
tissue as compared to sham and 2-wk diabetes groups.
Sepsis in 2-wk diabetic rats significantly increased the
expression of LV iNOS and decreased eNOS as com-
pared to sham and 2-wk diabetes groups. Also in 4-wk
diabetic rats sepsis significantly increased iNOS and
decreased eNOS as compared to sham and sepsis groups
(Fig. 4A and B).
5.8. LV total and phosphorylated p38-MAPK
To determine the effect of sepsis in 2-wk and 4-wk
diabetes on p38-MAPK activation, we determined the
expression of pp38-MAPK (Fig. 5A) and total p38-MAPK
(Fig. 5B) in LV tissue. A significant up-regulation of total
and phosphorylated LV p38-MAPK was observed in
sepsis group as compared to sham. Two-week diabetes
did not alter phosphorylated and total p38-MAPK as
compared to sham. However, 4-wk diabetes produced a
significant increase in phosphorylated and total p38-
MAPK as compared to sham. Sepsis in 2-wk and 4-wk
diabetic rats significantly elevated both total and phos-
phorylated p38-MAPK as compared to sham. Also LV
p38-MAPK phosphorylation was significantly increased in
4-wk diabetic + septic rats as compared to sepsis and 2-wk
diabetes + sepsis groups (Fig. 5).
5.9. LV total and phosphorylated ERK1/2
The effect of sepsis in diabetic rats on the phosphor-
ylation of ERK1/2 was examined as two 44- and 42-kDa
bands in LV tissue. Diabetes, both 2-wk and 4-wk,
produced a significant increase in the protein expression
of LV total (Fig. 6B) and phosphorylated ERK1/2 (Fig.
6A) as compared to sham group. Sepsis did not alter total
and phosphorylated ERK1/2 in LV tissue. However, 2-wk
and 4-wk diabetes + sepsis groups exhibited a significant
increase in LV phosphorylated ERK1/2 as compared to
sham and sepsis groups (Fig. 6).
5.10. Phosphorylation of LV Hsp27
To examine if LV p38-MAPK phosphorylation activat-
ed the downstream effectors during sepsis in diabetes, the
protein expression of phosphorylated Hsp 27 was deter-
mined. Phosphorylated LV Hsp27 was significantly in-
creased in 4-wk diabetes groups but not in the 2-wk
diabetic group as compared to sham. Sepsis also increased
LV phosphorylated Hsp27 expression as compared to
sham group. Sepsis in 2-wk and 4-wk diabetic groups
significantly increased LV phosphorylated Hsp27 expres-
sion as compared to sham. The increase in phosphorylated
Hsp27 expression in 4-wk diabetes + sepsis group was
Fig. 4. Effect of sepsis on the protein expression of (A) inducible NOS (iNOS) and (B) endothelial NOS (eNOS) in the left ventricular tissue obtained from
sham and STZ-treated (2-wk and 4-wk) animals (N = 3 in each group). Data are expressed as meanF S.E. The blot in each case is a representative of three
independent experiments. D2, 2-wk diabetes group; D4, 4-wk diabetes group; D2 + sepsis, 2-wk diabetes + sepsis group; D4 + sepsis, 4-wk diabetes + sepsis
group. *PV 0.05 as compared to sham-treated group, #PV 0.05 as compared to sepsis group, aPV 0.05 as compared to respective 2-wk group and yPV 0.05 as
compared to 2-wk diabetes group.
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sis groups (Fig. 7).6. Discussion
The present study demonstrated that polymicrobial
sepsis elevated TNF-a, ET-1 and NO generation in 4-wk
diabetic rats. We further found evidence that sepsis poten-
tiated diabetes-induced elevated LVEDP and LV p38-
MAPK phosphorylation depending upon the duration of
hyperglycemia in the rat. These data suggest that an up-
regulation of p38-MAPK and ERK1/2 phosphorylation
along with altered biosynthesis of ET-1 and NO, following
progression from 2-wk to 4-wk diabetes, can contribute to
secondary myocardial complications found in diabetic
subjects.STZ induced type 2 diabetes in rodents is a well-
established model characterized by insulin deficiency asso-
ciated with insulin resistance [25]. STZ produces pancreatic
beta cell necrosis and DNA damage through superoxide
production [26]. Bar-On et al. [27] reported that STZ (55
mg/kg i.v) caused increased plasma glucose levels, reduced
body weight and a mortality of 17% in rats. Similarly in this
study too, we have observed 20% and 26% mortality in 2-
wk and 4-wk diabetes groups, respectively. The rats were
hyperglycemic and lost weight 17% and 20% following 2-
wk and 4-wk of diabetes induction using STZ. Although no
changes in MAP and LVEDP were observed in 2-wk
diabetes group, 4-wk diabetic rats exhibited an increased
LVEDP. We and other research groups have reported that
LVEDP alterations occur much earlier than changes in rates
of LV contractility ( + dP/dt and  dP/dt), and therefore can
be used as an early marker for CHF [28], sepsis [29] and
Fig. 5. Effect of sepsis on protein expression of (A) phosphorylated p38-mitogen activated protein kinase (p38-MAPK) and (B) total p38-MAPK in the left
ventricular tissue obtained from sham and STZ-treated (2-wk and 4-wk) animals (N = 3 in each group). Data are expressed as meanF S.E. The blot in each case
is a representative of three independent experiments. D2, 2-wk diabetes group; D4, 4-wk diabetes group; D2 + sepsis, 2-wk diabetes + sepsis group; D4 + sepsis,
4-wk diabetes + sepsis group. *PV 0.05 as compared to sham-treated group, #PV 0.05 as compared to sepsis group, aPV 0.05 as compared to respective 2-wk
group and yPV 0.05 as compared to 2-wk diabetes group.
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present study support our contention that STZ-induced
hyperglycemia produced LVEDP alterations indicating an
early stage of CHF during progression from 2-wk to 4-wk
diabetes. Mihm et al. [30] have also reported similar
hemodynamic alterations during 7 days and 35 days post-
STZ. In addition, we have also observed decrease in
myocardial oxygen demand (RPP) in diabetic rats which
correlates well with HR. Similar observations were made by
Law et al. [31] in a 4-wk diabetic canine model where they
demonstrated a decreased myocardial oxygen demand.
Diabetes exacerbates infections (gram-positive and gram-
negative) and renders patients susceptible to infection [32].
These infections are related to invasive procedures such as
chronic peritoneal dialysis, hemodialysis and vascular ac-
cess device, etc. [33]. The cecal inoculum used in the
present study to induce sepsis consists of both gram-positiveand gram-negative microorganisms [34]. Sepsis-induced
SIRS is a complex array of clinical conditions including
hypotension, blood coagulopathy and increased capillary
permeability that can lead to organ failure [35]. Sepsis
releases several proinflammatory cytokines like TNF-a,
IL-1 and IL-6 [35]. We have also found elevated plasma
TNF-a in septic rats but not in diabetic animals suggesting
that progression from 2-wk to 4-wk diabetes is not associ-
ated with development of SIRS as seen during sepsis.
Although sepsis did not increase the concentration of
circulating TNF-a during 2-wk diabetes, it caused a f 2-
fold increase in 4-wk diabetes. These data demonstrate that
sepsis-induced active SIRS, characterized by elevated TNF-
a, was evident at 4-wk diabetes but not at 2-wk. However,
the lack of elevated TNF-a in 2-wk diabetes following
sepsis could be due to activation of anti-inflammatory
cytokines like IL-10 which are known to control excessive
Fig. 6. Effect of sepsis on the protein expression of (A) phosphorylated extracellular signal regulated kinase (p-ERK1/2) and (B) total ERK (T-ERK1/2) in the
left ventricular tissue obtained from sham and STZ-treated (2-wk and 4-wk) animals (N= 3 in each group). Data are expressed as meanF S.E. The blot in each
case is a representative of three independent experiments. D2, 2-wk diabetes group; D4, 4-wk diabetes group; D2+ sepsis, 2-wk diabetes + sepsis group;
D4 + sepsis, 4-wk diabetes + sepsis group, *PV 0.05 as compared to sham-treated group and #PV 0.05 as compared to sepsis group.
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duration of hyperglycemia from 2 wk to 4 wk produces
more severe SIRS following sepsis.
Overt myocardial dysfunction has been attributed to an
active SIRS following polymicrobial sepsis and diabetes
characterized by reduced LV pressure development and
relaxation ( + dP/dt and  dP/dt, respectively) and reduced
peak ventricular pressure development in vitro [4,6]. In a
diabetic dog model Law et al. [31] have demonstrated that
induction of endotoxemia produced depressed left ventric-
ular contraction. However, the current study elucidates LV
dysfunction in a more clinically relevant study as opposed to
the one carried out by Law et al. In the present in vivo study
sepsis produced an elevation in LVEDP that was further
increased in 4-wk diabetic animals. Also, RPP was de-
creased following sepsis in 2-wk and 4-wk diabetes. Since
RPP is a function of HR and SBP it appears that changes inRPP are being reflected due to changes in HR. In our study
we have found that sepsis produced depressed left ventric-
ular contraction in 4-wk diabetic groups suggesting a
deteriorating effect of sepsis in 4-wk diabetic rats. Hence,
it appears that a septic insult disposes the myocardium
towards LV dysfunction during 2-wk diabetes that becomes
more severe during 4-wk diabetes in the rat.
Elevated [36], unchanged [37] and attenuated [38] plas-
ma ET-1 levels have been reported during diabetes. Al-
though the reason for such a variation in findings appears
difficult to fathom, the discrepancies in data may be
attributed to differences in species of animals, duration of
hyperglycemia, dose of STZ administered, etc. In a STZ-
induced diabetes rat model we have observed an increase in
ET-1 concentration in plasma and LV tissue during 4-wk but
not in 2-wk diabetes. These results were further supported
by up-regulated LV preproET-1 protein expression during
Fig. 7. Effect of sepsis on protein expression of phosphorylated heat shock
protein-27 (Hsp27) in the left ventricular tissue obtained from sham and
STZ-treated (2-wk and 4-wk) animals (N= 3 in each group). Data are
expressed as meanF S.E.M. The blot in each case is a representative of
three independent experiments. D2, 2-wk diabetes group; D4, 4-wk
diabetes group; D2 + sepsis, 2-wk diabetes + sepsis group; D4 + sepsis, 4-
wk diabetes + sepsis group, *PV 0.05 as compared to sham-treated group,
#PV 0.05 as compared to sepsis group, aPV 0.05 as compared to respective
2-wk group.
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diabetic rats, both plasma and LV ET-1 concentrations were
elevated. It appears that although sepsis can activate ET
mechanisms both in 2-wk and 4-wk diabetes, the elevation
of LV ET-1 and expression of preproET-1 were more
pronounced in 4-wk diabetic rats. These data suggest that
induction of sepsis activates LV ET-1 mechanisms during
diabetes and can contribute to cardiovascular alterations
such as elevated LVEDP as seen in diabetic subjects. Since
ET-1 genes are expressed in heart and isolated ventricular
myocytes [39], we speculate that prolonged hyperglycemia
renders the heart susceptible to ET-1 gene activation via an
active SIRS. Although the mechanisms of ET-1 increase
during diabetes are relatively unknown, several research
groups speculated that this could be due to an abnormal
production by the affected endothelium [40]; or lack of
suppression of ET-1 release secondary to attenuated endo-
thelium-derived relaxing factor production [41]. However,
further studies will be required to explore the mechanism of
ET-1 elevation following sepsis in diabetic rats.
Besides ET-1, NO is another potent vasomediator that not
only regulates vascular function but also causes myocardial
depression [6,17,18]. Various studies have been carried out to
explore the influence of diabetes on NOS activation. Stock-
klauser-Farber et al. [19] have reported that myocardial NOS
(iNOS and eNOS) activity increased and reached maximal
values after diabetes duration of 4 wk and 6 wk. In the present
study, progression of diabetes from 2wk to 4 wk up-regulated
iNOS while down-regulating eNOS expression that corre-
lates well with elevated LVEDP and systemic and local
increase in NOx levels. This suggests that NO stimulation
in the myocardium occurs with increased duration of hyper-glycemia in STZ-induced diabetic rats. Similar to our earlier
studies, an increased expression of iNOS and depressed
expression of eNOS was seen following sepsis [42]. Unlike
2-wk diabetic group, sepsis induction in these animals
produced elevated expression of LV iNOS along with de-
pressed eNOS and increased NOx levels. These data suggest
that sepsis activated LV NO mechanisms in 2-wk diabetes.
Similar results were obtained following sepsis induction in 4-
wk diabetes group, which were more pronounced than in
sepsis during 2-wk diabetes. These results indicate that
polymicrobial sepsis in diabetic rat exacerbates iNOS acti-
vation that may account for elevated NOx concentration
locally and systemically in the rat.
In the present study down-regulation of myocardial
eNOS along with increased iNOS and NOx during both
diabetes and sepsis is intriguing. Recent studies have
demonstrated that high concentrations of NO as would be
produced after iNOS induction inhibit eNOS activity and
expression [43]. Similar to our findings, Zhao et al. [20]
have shown this in alloxan-induced diabetes in dogs; a
twofold increase in iNOS mRNA expression was accompa-
nied with a decrease in eNOS protein expression. Similar
elevation of iNOS along with depression of eNOS was also
seen in heart and thoracic aorta following endotoxemia in
the rat [23,44]. We speculate that depression in eNOS
expression in 4-wk diabetes and sepsis during 2-wk and
4-wk diabetes could be due to excessive NO generation by
iNOS induction. Hyperglycemia itself has been shown to
possess a variable response on eNOS in different cell types
[45–47]. Since in the present study both ET-1 and iNOS
activations exhibit a similar course during sepsis in diabetic
rats, we speculate that iNOS stimulation could be due to
activation of ETB receptors via elevated ET-1 mechanisms
[48].
6.1. Signaling mechanisms following sepsis in diabetics
The present study provides evidence for the involvement
of LV MAPK cascade in sepsis following STZ-induced
diabetes. MAPKs can be activated by stress stimulation of
Gq-protein-coupled-receptors by ET-1 [11]. Hyperglycemia
has been shown to phosphorylate ERK1/2 in rat glomerular
and mesangial cells [9] and p38-MAPK in vascular smooth
muscle cells and aorta derived from diabetic rats [49]. In the
present study we observed that 2-wk diabetes up-regulated
LV ERK1/2 but did not affect p38-MAPK phosphorylation.
However, 4-wk diabetes activated both LV p38-MAPK and
ERK1/2. These findings suggest that protective mechanisms
mediated by ERK1/2 phosphorylation predominate during
2-wk diabetes. Sepsis also up-regulated LV p38-MAPK
phosphorylation during both 2-wk and 4-wk diabetes. It
was further observed that LV p38-MAPK phosphorylation
was more pronounced following sepsis in 4-wk than in 2-wk
diabetes. These data were supported by the observation that
sepsis in 4-wk diabetic rats up-regulates the phosphorylation
of Hsp27, a downstream effector of the p38-MAPK cascade
A. Gupta et al. / Biochimica et Biophysica Acta 1690 (2004) 42–5352[50]. However, unlike phosphorylated p38-MAPK, ERK1/2
phosphorylation was not altered following sepsis in 4-wk
diabetes as opposed to sepsis during 2-wk diabetes. The data
suggest that sepsis activates p38-MAPK but not ERK1/2
phosphorylation, which correlates with LVEDP alterations
depending upon the duration of hyperglycemia following
diabetes.
Activation of iNOS can occur due to several pathways
including binding of ET-1 to ETB receptor [48], ERK1/2
[51] and p38-MAPK [14]. In the present study we observed
that ERK1/2 precedes p38-MAPK phosphorylation depend-
ing upon the progression of diabetes from 2 wk to 4 wk.
Although we did not find NOS activation during 2-wk
diabetes, we observed a profound increase in NOx levels
and iNOS expression along with a corresponding increase in
p38-MAPK activation during 4 wk. We propose that p38-
MAPK activation could be an important signaling mecha-
nism that causes iNOS activation as was reported by Liu et
al. [14]. Similar findings were also reported by Song et al.
[8] where they demonstrated that iNOS regulates immune
dysfunction by p38-MAPK activation during sepsis. These
findings suggest that in diabetes phosphorylation of p38-
MAPK and not ERK1/2 is associated with iNOS activation
and LVEDP dysfunction following sepsis. We also speculate
that activated p38-MAPK and iNOS during 4-wk diabetes
and diabetes + sepsis outweigh myocardial ERK1/2 mecha-
nisms. A similar finding, though not directly related to the
present study, was shown by Purves et al. [52] where they
demonstrated using cultured sensory neurons that cotreat-
ment with high glucose and oxidative stress results in an
additive effect on p38-MAPK phosphorylation without any
additional effect on ERK1/2 activation. However, studies
are required to further delineate ERK1/2 and p38-MAPK
pathways during sepsis in diabetes.
The findings of the present study suggest that sepsis
caused a factorial increase in LV p38-MAPK phosphoryla-
tion along with iNOS and Hsp27 up-regulation following
progression from 2-wk to 4-wk diabetes. The study provides
evidence that sepsis up-regulated LV p38-MAPK phosphor-
ylation and elevated LVEDP during 4-wk diabetes. We
concluded that sepsis contributes in the development of
LVEDP dysfunction and alteration in signaling mechanisms
depending upon the progression from 2-wk to 4-wk diabetes
in the rat. However, more studies will be required to
determine the inherent link or interaction between p38-
MAPK up-regulation, ET-1 and NO mechanisms in the
development of CHF during sepsis in diabetic subjects.Acknowledgements
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